Calcitonin measurement and immunoassay interference: a case report and literature review
暂无分享,去创建一个
S. Barollo | L. Bertazza | C. Mian | M. Plebani | L. Zambonin | M. Zaninotto | S. Censi | E. Cavedon | S. W. Fernando | D. Faggian
[1] J. Vieira,et al. Macrocalcitonin Is a Novel Pitfall in the Routine of Serum Calcitonin Immunoassay. , 2016, The Journal of clinical endocrinology and metabolism.
[2] P. Trimboli,et al. Use of fine‐needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review , 2016, Diagnostic cytopathology.
[3] Douglas B. Evans,et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.
[4] P. Trimboli,et al. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. , 2015, Endocrine-related cancer.
[5] G. Cevenini,et al. Reference range of serum calcitonin in pediatric population. , 2015, The Journal of clinical endocrinology and metabolism.
[6] P. Trimboli,et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta‐analysis , 2015, Clinical endocrinology.
[7] R. Vigneri,et al. Cardiac arrest after intravenous calcium administration for calcitonin stimulation test. , 2014, Thyroid : official journal of the American Thyroid Association.
[8] M. Pelizzo,et al. Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. , 2014, The Journal of clinical endocrinology and metabolism.
[9] P. Trimboli,et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study , 2014, Clinical endocrinology.
[10] P. Trimboli,et al. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules , 2013, Clinical chemistry and laboratory medicine.
[11] R. Castello,et al. Thyroid volume influences serum calcitonin levels in a thyroid-healthy population: results of a 3-assay, 519 subjects study , 2012, Clinical chemistry and laboratory medicine.
[12] M. Pelizzo,et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. , 2012, The Journal of clinical endocrinology and metabolism.
[13] C. Sturgeon,et al. Analytical error and interference in immunoassay: minimizing risk , 2011, Annals of clinical biochemistry.
[14] M. Rugge,et al. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. , 2011, European journal of endocrinology.
[15] L. Giovanella,et al. Spurious hypercalcitoninemia and heterophilic antibodies in patients with thyroid nodules , 2011, Head & neck.
[16] P. Perros,et al. 2009 American Thyroid Association guidelines on thyroid nodules. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).
[17] S. Kim,et al. Spurious hypercalcitoninemia in patients with nodular thyroid disease induced by heterophilic antibodies , 2009, Head & neck.
[18] M. Luster,et al. Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. , 2009, The Journal of clinical endocrinology and metabolism.
[19] H. Gharib,et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.
[20] P. Caron,et al. Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. , 2007, European journal of endocrinology.
[21] J. Lee,et al. Diffuse sclerosing variant of papillary carcinoma of the thyroid: imaging and cytologic findings. , 2007, Thyroid : official journal of the American Thyroid Association.
[22] M. Tommasi,et al. Comparison of calcitonin determinations by polyclonal and monoclonal IRMAs. , 2007, Clinical chemistry.
[23] R. Sherwood,et al. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial , 1992, Cell Biophysics.
[24] H. Karga,et al. Heterophilic antibodies causing falsely high serum calcitonin values , 2006, Journal of endocrinological investigation.
[25] S. Berson,et al. General principles of radioimmunoassay. 1968. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[26] M. Langlois,et al. "Hook effect" in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature. , 2006, The Journal of clinical endocrinology and metabolism.
[27] A. Ismail. A radical approach is needed to eliminate interference from endogenous antibodies in immunoassays. , 2005, Clinical chemistry.
[28] D. O'Kane,et al. Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. , 2005, Clinical chemistry.
[29] E. Mallet,et al. Reference intervals for serum calcitonin in men, women, and children. , 2004, Clinical chemistry.
[30] J. White,et al. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. , 2004, The Journal of clinical endocrinology and metabolism.
[31] E. Seregni,et al. Evaluation of Circulating Calcitonin: Analytical Aspects , 2003, Tumori.
[32] S. S. Levinson,et al. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. , 2002, Clinica chimica acta; international journal of clinical chemistry.
[33] V. Marks,et al. False-positive immunoassay results: a multicenter survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries. , 2002, Clinical chemistry.
[34] J. Barth,et al. Interference in immunoassay is an underestimated problem , 2002, Annals of clinical biochemistry.
[35] M. Mannelli,et al. False serum calcitonin high levels using a non-competitive two-site IRMA , 2001, Journal of endocrinological investigation.
[36] A. Remaley,et al. A case of spurious hypercalcitoninemia: A cautionary tale on the use of plasma calcitonin assays in the screening of patients with thyroid nodules for neoplasia , 2001, Journal of endocrinological investigation.
[37] A. Bockisch,et al. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. , 2000, The Journal of clinical endocrinology and metabolism.
[38] L. Cole,et al. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations , 2000, The Lancet.
[39] L J Kricka,et al. Human anti-animal antibody interferences in immunological assays. , 1999, Clinical chemistry.
[40] I. Kaplan,et al. When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen. , 1999, Clinical chemistry.
[41] D. Chappard,et al. Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study. , 1997, The Journal of clinical endocrinology and metabolism.
[42] G. Hör,et al. Activating anti‐idiotypic human anti‐mouse antibodies for immunotherapy of ovarian carcinoma , 1994, Cancer.
[43] L. Boscato,et al. Heterophilic antibodies: a problem for all immunoassays. , 1988, Clinical chemistry.
[44] P. J. Howanitz,et al. Incidence and mechanism of spurious increase in serum thyrotropin. , 1982, Clinical chemistry.
[45] P. Thomopoulos,et al. False hyperthyrotropinemia induced by heterophilic antibodies against rabbit serum. , 1981, The Journal of clinical endocrinology and metabolism.
[46] R. Dawkins,et al. Population Study of Heterophile Antibodies , 1980, Vox sanguinis.
[47] S. Berson,et al. General principles of radioimmunoassay. , 1968, Clinica chimica acta; international journal of clinical chemistry.
[48] C. Hales,et al. Labelled Antibodies and Immunological Assay Systems , 1968, Nature.
[49] A. Cameron,et al. Delay in seeking treatment for mammary tumors , 1968, Cancer.